477 related articles for article (PubMed ID: 21538283)
1. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
2. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
3. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
Hunt JP; Varnholt H
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
[No Abstract] [Full Text] [Related]
4. Copy number aberrations in combined hepatocellular carcinoma and cholangiocarcinoma.
You HL; Weng SW; Li SH; Wei YC; Sheu JJ; Chen CM; Huang WT
Exp Mol Pathol; 2012 Jun; 92(3):281-6. PubMed ID: 22366251
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
6. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
[TBL] [Abstract][Full Text] [Related]
7. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
[TBL] [Abstract][Full Text] [Related]
9. Genetic classification of combined hepatocellular-cholangiocarcinoma.
Fujii H; Zhu XG; Matsumoto T; Inagaki M; Tokusashi Y; Miyokawa N; Fukusato T; Uekusa T; Takagaki T; Kadowaki N; Shirai T
Hum Pathol; 2000 Sep; 31(9):1011-7. PubMed ID: 11014564
[TBL] [Abstract][Full Text] [Related]
10. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.
Cazals-Hatem D; Rebouissou S; Bioulac-Sage P; Bluteau O; Blanché H; Franco D; Monges G; Belghiti J; Sa Cunha A; Laurent-Puig P; Degott C; Zucman-Rossi J
J Hepatol; 2004 Aug; 41(2):292-8. PubMed ID: 15288479
[TBL] [Abstract][Full Text] [Related]
12. Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.
Liu B; Hervé J; Bioulac-Sage P; Valogne Y; Roux J; Yilmaz F; Boisgard R; Guettier C; Calès P; Tavitian B; Samuel D; Clerc J; Bréchot C; Faivre J
Gastroenterology; 2007 Apr; 132(4):1495-503. PubMed ID: 17408651
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
14. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Sia D; Villanueva A; Friedman SL; Llovet JM
Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
[TBL] [Abstract][Full Text] [Related]
15. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.
Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN
Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953
[TBL] [Abstract][Full Text] [Related]
16. p53 Mutations in human cholangiocarcinoma: a review.
Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD
Liver Int; 2005 Aug; 25(4):704-16. PubMed ID: 15998419
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
Tannapfel A; Sommerer F; Benicke M; Katalinic A; Uhlmann D; Witzigmann H; Hauss J; Wittekind C
Gut; 2003 May; 52(5):706-12. PubMed ID: 12692057
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
I Ilyas S; Borad MJ; Patel T; Gores GJ
Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
[TBL] [Abstract][Full Text] [Related]
19. High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas.
Fiorentino M; D'Errico A; Altimari A; Barozzi C; Grigioni WF
Diagn Mol Pathol; 1999 Dec; 8(4):189-94. PubMed ID: 10617275
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
